stockrow
Saturday 7 November 2026
Export RAPP’s income statement to Excel — free account
Rapport Therapeutics, Inc.
RAPP Healthcare Biotechnology
- EPS
- −18.6%
- Free cash flow
- −64.8%
Quarter to September 2026, against a year earlier
24.48
0.76
+3.20%
Follow RAPP
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(28.22%) | (28.33%) | (39.96%) | (33.33%) | |
| (26.95%) | (26.83%) | (36.85%) | (31.55%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(23.11%) | (22.86%) | (32.60%) | (38.68%) | |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.26) | (1.71) | (2.04) | (2.53) | |
Free Cash Flow |
(88.09) | (80.71) | (96.96) | (120.78) | |
Capital Expenditures |
(0.62) | (0.41) | (0.27) | 0.07 | |
| Other line items | |||||
Cash ROIC |
(9.03%) | (8.51%) | (11.29%) | (15.36%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.78 | 0.75 | 0.70 | 0.80 | |
Depreciation/Fixed assets |
(0.13) | (0.13) | 0.03 | (0.25) | |
Capex/Depreciation |
1.63 | 1.27 | (3.75) | (0.14) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.25) | (1.70) | (2.04) | (2.53) | |
Capex per Share |
(0.02) | (0.01) | (0.01) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026